HCM - ハチソン・チャイナ・メディテック (Hutchison China MediTech Limited) ハチソン・チャイナ・メディテック

 HCMのチャート


 HCMの企業情報

symbol HCM
会社名 Hutchison China Meditech Ltd (ハチソン・チャイナ・メディテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   ハチソン・チャイナ・メディテックはケイマン諸島籍で中国医薬品メ―カ―。主に抗がん剤や自己免疫疾患治療向けの医薬品の開発・製造・販売に従事する。また、植物成分に由来する中国伝統の漢方薬、健康補助食品、オ―ガニック食品ヘルスケア用品、パ―ソナルケア用品なども取り扱う。本社所在地は香港。   
本社所在地 22/F Hutchison House 10 Harcourt Road HKG
代表者氏名
代表者役職名
電話番号
設立年月日 36861
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 590人
url www.chi-med.com
nasdaq_url https://www.nasdaq.com/symbol/hcm
adr_tso 29546022
EBITDA EBITDA ー
終値(lastsale) 30.42
時価総額(marketcap) 898789989.24
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 HCMのテクニカル分析


 HCMのニュース

   Hutchmed, Epizyme cancer drug Tazverik gets China''s Hainan province health regulator nod  2022/06/01 10:41:10 Seeking Alpha
Hutchmed (China) Epizyme''s (EPZM) cancer drug Tazverik (tazemetostat) was approved by the Health Commission and Medical Products Administration of Hainan Province.Tazverik can now be…
   HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China  2022/06/01 08:33:00 GlobeNewswire
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK ® (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot Zone”), under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma (“ES”) and follicular lymphoma (“FL”) consistent with the label as approved by the U.S. Food and Drug Administration (“FDA”). Launched in 2013 and located in China, the Hainan Pilot Zone is a destination for international medical tourism and global hub for scientific innovation, welcoming 83,900 medical tourists in 2020, according to official data.
   HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China  2022/06/01 08:33:00 Wallstreet:Online
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK (tazemetostat) has been approved by the Health Commission and Medical Products Administration of Hainan Province to be used in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (“Hainan Pilot
   Boom Or Bust: Where Is HUTCHMED (China) Limited (NASDAQ: HCM) Stock Headed Next?  2022/05/28 13:30:00 Marketing Sentinel
HUTCHMED (China) Limited (NASDAQ:HCM)’s traded shares stood at 0.54 million during the last session, with the company’s beta value hitting 1.27. At the close of trading, the stock’s price was $9.56, to imply an increase of 5.52% or $0.5 in intraday trading. The HCM share’s 52-week high remains $43.94, putting it -359.62% down since that … Boom Or Bust: Where Is HUTCHMED (China) Limited (NASDAQ: HCM) Stock Headed Next? Read More »
   INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm  2022/05/27 16:05:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
   U.S. FDA Rejects HUTCHMED''s New Drug Application For Surufatinib In Neuroendocrine Tumors  2022/05/02 12:43:45 Benzinga
HUTCHMED (China) Limited (Nasdaq: HCM ) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs). The regulatory agency determined that the current data package, based … Full story available on Benzinga.com
   Hutchmed''s China-tested cancer drug fails to get US approval  2022/05/02 11:17:13 Times LIVE
Hutchmed Ltd said on Monday the US Food and Drug Administration has declined to approve its cancer drug, citing the need for a multi-regional clinical trial, becoming the second China-tested drug to be rejected by the US regulator this year.
   Hutchmed stock falls as FDA rejects surufatinib to treat neuroendocrine tumors  2022/05/02 10:51:10 Seeking Alpha
The U.S. Food and Drug Administration rejected Hutchmed''s (China) (HCM) application seeking approval of surufatinib to treat certain neuroendocrine tumors citing that the data…
   Hutchmed’s China-tested cancer drug fails to get U.S. approval  2022/05/02 10:46:58 Financial Post
Hutchmed Ltd said on Monday the U.S. Food and Drug Administration has declined to approve its cancer drug, citing the need for a multi-regional clinical trial, becoming the second China-tested drug to be rejected by the U.S. regulator this year. In its so-called complete response letter to the company, the FDA said current drug data, […]
   HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors  2022/05/02 10:00:00 GlobeNewswire
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT
   City of Olathe selects Avaap to deploy new Workday solutions  2021/12/23 10:41:34 EnterpriseTimes
The City of Olathe, Kansas, is to deploy Workday solutions with the assistance of Avaap. The project is part of the ambitious Olathe 2040 strategic plan that aims to make the city future-ready. Avaap revealed that it would deploy Workday Financial Management, Workday Human Capital Management (HCM), and Workday Payroll. It will see the organisation deploy new payroll, time [] The post City of Olathe selects Avaap to deploy new Workday solutions appeared first on Enterprise Times .
   HUTCHMED (NASDAQ:HCM) Rating Lowered to Hold at Zacks Investment Research  2021/11/23 08:50:41 Transcript Daily
Zacks Investment Research downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a research note published on Monday morning, Zacks.com reports. According to Zacks, Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China []
   SmartLinx Taps HCM Veteran Michelle Northey to Drive Product Innovation for the Senior Care Industry  2021/11/19 14:44:18 TecHR Series
Michelle Northey Brings Over Two Decades of Industry Expertise to Lead Product at SmartLinx and Support Mission to Transform the Way the Healthcare Industry Supports Employees and Delivers Care SmartLinx, a leading provider of cloud-based workforce management solutions for senior care, announces the appointment of Michelle Northey as Chief Product Officer. At SmartLinx, Ms. Northey will [] The post SmartLinx Taps HCM Veteran Michelle Northey to Drive Product Innovation for the Senior Care Industry appeared first on TecHR .
   United States: Employee Benefits Administration Software Market Assessment Report 2020-2026 | BambooHR, Ceridian, Employee Navigator, ISolved HCM, Penad Pension Services, PeopleKeep, PLEXIS Healthcare Systems, RiseSmart  2021/11/08 00:36:57 Cheshire Media
Worldwide Market Reports added Employee Benefits Administration Software Market to its vast collection of research Database. The report classifies the United States Employee Benefits Administration Software Market in a precise manner to offer detailed insights into the aspects responsible for augmenting as well as restraining market growth. A comprehensive analysis of the United States Employee []
   Datavail Acquires Oracle Consultancy, Google Cloud Partner Skybridge Global  2021/11/05 14:57:18 ChannelE2E
Managed database service provider Datavail buys Skybridge Global, an Oracle ERP and HCM partner, and Google cloud consultancy. The post Datavail Acquires Oracle Consultancy, Google Cloud Partner Skybridge Global appeared first on ChannelE2E .

 関連キーワード  (― 米国株 ハチソン・チャイナ・メディテック HCM Hutchison China MediTech Limited)

 twitter  (公式ツイッターやCEOツイッターなど)